Milind A Phadnis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/704707/publications.pdf

Version: 2024-02-01

42 papers 476 citations

687363 13 h-index 752698 20 g-index

47 all docs

47 docs citations

47 times ranked

676 citing authors

#	Article	IF	CITATIONS
1	Potent Antiplatelet Therapy May Reduce Death from Sepsis in Patients on Chronic Dialysis. American Journal of Cardiology, 2022, 162, 209-211.	1.6	3
2	CA209-8YD: A phase I/II trial of rucaparib in combination with ramucirumab with or without nivolumab in previously treated advanced gastroesophageal adenocarcinoma (GEA) (RiME) Journal of Clinical Oncology, 2022, 40, TPS377-TPS377.	1.6	0
3	Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results Journal of Clinical Oncology, 2022, 40, 135-135.	1.6	17
4	A phase II study of perioperative mFOLFOX chemotherapy plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ), and stomach Journal of Clinical Oncology, 2022, 40, 329-329.	1.6	5
5	Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis. Kidney360, 2022, 3, 1374-1383.	2.1	1
6	Design and Basic Characteristics of a National Patient-Powered Registry in ADPKD. Kidney360, 2022, 3, 1350-1358.	2.1	4
7	Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT) Journal of Clinical Oncology, 2022, 40, 513-513.	1.6	36
8	Phase Ib/IIa trial of CENDâ€1 in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colorectal, and appendiceal cancers (CENDIFOX) Journal of Clinical Oncology, 2022, 40, TPS4195-TPS4195.	1.6	2
9	A phase II study of perioperative mFOLFOX plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ) and stomach Journal of Clinical Oncology, 2022, 40, 4047-4047.	1.6	3
10	Accurate Medication Adherence Measurement Using Administrative Data for Frequently Hospitalized Patients. Hospital Pharmacy, 2021, 56, 451-461.	1.0	O
11	Sample size calculations for noninferiority trials for time-to-event data using the concept of proportional time. Journal of Applied Statistics, 2021, 48, 1009-1032.	1.3	O
12	Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage l–III Triple-negative Breast Cancer (NeoSTOP). Clinical Cancer Research, 2021, 27, 975-982.	7.0	51
13	Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3896-3904.	7.0	36
14	Some design considerations incorporating early futility for <scp>singleâ€arm</scp> clinical trials with timeâ€toâ€event primary endpoints using Weibull distribution. Pharmaceutical Statistics, 2021, 20, 610-644.	1.3	3
15	Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC) Journal of Clinical Oncology, 2021, 39, 1076-1076.	1.6	7
16	Sample size calculation for twoâ€arm trials with timeâ€toâ€event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions. Biometrical Journal, 2021, 63, 1406-1433.	1.0	4
17	Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis. Kidney International Reports, 2021, 6, 2381-2391.	0.8	5
18	Group sequential design for time-to-event data using the concept of proportional time. Statistical Methods in Medical Research, 2020, 29, 1867-1890.	1.5	5

#	Article	IF	CITATIONS
19	A comparison of diabetes self-care behavior in people with type 2 diabetes with and without insomnia symptoms. Acta Diabetologica, 2020, 57, 651-659.	2.5	5
20	Sleep Efficiency and Total Sleep Time in Individuals with Type 2 Diabetes with and without Insomnia Symptoms. Sleep Disorders, 2020, 2020, 1-12.	1.4	1
21	Using Cognitive Behavioral Therapy for Insomnia in People with Type 2 Diabetes, Pilot RCT Part I: Sleep and Concomitant Symptom. Behavioral Sleep Medicine, 2020, 19, 1-20.	2.1	8
22	The effects of cognitive behavioral therapy for insomnia in people with type 2 diabetes mellitus, pilot RCT part II: diabetes health outcomes. BMC Endocrine Disorders, 2020, 20, 136.	2.2	20
23	Shorter length of hospital stay for hip fracture in those with dementia and without a known diagnosis of osteoporosis in the USA. BMC Geriatrics, 2020, 20, 523.	2.7	11
24	Assessing accuracy of Weibull shape parameter estimate from historical studies for subsequent sample size calculation in clinical trials with time-to-event outcome. Contemporary Clinical Trials Communications, 2020, 17, 100548.	1.1	6
25	Improving the efficiency of clinical trials by standardizing processes for Investigator Initiated Trials. Contemporary Clinical Trials Communications, 2020, 18 , 100579 .	1.1	3
26	Inertial sensors identified asymmetries in shank angular velocity at different gait speeds in individuals with anterior cruciate ligament reconstruction. Gait and Posture, 2020, 80, 302-307.	1.4	0
27	Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis. Cardiovascular Drugs and Therapy, 2019, 33, 511-521.	2.6	5
28	Sample size calculation for small sample single-arm trials for time-to-event data: Logrank test with normal approximation or test statistic based on exact chi-square distribution?. Contemporary Clinical Trials Communications, 2019, 15, 100360.	1.1	10
29	Effect of Cognitive Behavioral Therapy for Insomnia on Insomnia Symptoms for Individuals With Type 2 Diabetes: Protocol for a Pilot Randomized Controlled Trial. JMIR Research Protocols, 2019, 8, e14647.	1.0	7
30	Retrospective Analysis of Intrathecal Drug Delivery: Outcomes, Efficacy, and Risk for Cancer-Related Pain at a High Volume Academic Medical Center. Neuromodulation, 2018, 21, 660-664.	0.8	24
31	Association Between Gestational Diabetes and Incident Maternal CKD: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. American Journal of Kidney Diseases, 2018, 71, 112-122.	1.9	25
32	Effect of Long-term Nicotine Replacement Therapy vs Standard Smoking Cessation for Smokers With Chronic Lung Disease. JAMA Network Open, 2018, 1, e181843.	5.9	21
33	Association of Slow Graft Function with Long-Term Outcomes in Kidney Transplant Recipients. Annals of Transplantation, 2018, 23, 224-231.	0.9	17
34	An ensemble survival model for estimating relative residual longevity following stroke: Application to mortality data in the chronic dialysis population. Statistical Methods in Medical Research, 2017, 26, 2667-2680.	1.5	2
35	A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution. Statistics in Medicine, 2017, 36, 4121-4140.	1.6	9
36	Retrospective data suggests that the higher prevalence of benign paroxysmal positional vertigo in individuals with type 2 diabetes is mediated by hypertension. Journal of Vestibular Research: Equilibrium and Orientation, 2016, 25, 233-239.	2.0	41

#	Article	IF	CITATIONS
37	Ambulatory Status Protects against Venous Thromboembolism in Acute Mild Ischemic Stroke Patients. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 2496-2501.	1.6	4
38	Association of multiple ischemic strokes with mortality in incident hemodialysis patients: an application of multistate model to determine transition probabilities in a retrospective observational cohort. BMC Nephrology, 2016, 17, 134.	1.8	1
39	Effectiveness comparison of cardio-selective to non-selective \hat{l}^2 -blockers and their association with mortality and morbidity in end-stage renal disease: a retrospective cohort study. BMC Cardiovascular Disorders, 2016, 16, 60.	1.7	19
40	Estimation of Drug Effectiveness by Modeling Three Time-Dependent Covariates: An Application to Data on Cardioprotective Medications in the Chronic Dialysis Population. Statistics in Biopharmaceutical Research, 2014, 6, 229-240.	0.8	8
41	Race, Ethnicity, and State-by-State Geographic Variation in Hemorrhagic Stroke in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 756-763.	4.5	16
42	Stroke and the "Stroke Belt―in Dialysis: Contribution of Patient Characteristics to Ischemic Stroke Rate and Its Geographic Variation. Journal of the American Society of Nephrology: JASN, 2013, 24, 2053-2061.	6.1	30